# EU approves AstraZeneca’s Imfinzi with FLOT chemotherapy for early gastric cancer

- Link: https://www.directorstalkinterviews.com/eu-approves-astrazeneca-s-imfinzi-with-flot-chemotherapy-for-early-gastric-cancer/4121244668
- Published: 2026-03-16T07:33:28+00:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
_Imfinzi_ (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil,
leucovorin, oxaliplatin, and docetaxel) has been approved in the European Union (
EU) for the treatment of adult patients with resectable, early-stage and locally
advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers.
The regimen includes two cycles of _Imfinzi_ in combination with chemotherapy before
and after surgery, followed by _Imfinzi_ monotherapy.

The approval by the European Commission follows the positive opinion of the Committee
for Medicinal Products for Human Use and is based on the positive results from the
MATTERHORN Phase III trial_,_ which were published in The New England Journal of
Medicine_._

Gastric cancer is the fifth leading cause of cancer death globally, with nearly 
one million people diagnosed each year.^(1) In 2024, there were roughly 15,500 drug-
treated patients in the EU with early-stage and locally advanced gastric or GEJ 
cancer.^(2)

> **Josep Tabernero, MD, PhD, head of the Medical Oncology Department at Vall d’Hebron
> University Hospital and director of the Vall d’Hebron Institute of Oncology (VHIO)
> in  Barcelona, Spain, and principal investigator in the trial, said**: “Despite
> curative-intent surgery and chemotherapy, patients with resectable gastric and
> gastroesophageal cancers still face high recurrence rates and an urgent need for
> improved long-term survival. In MATTERHORN, nearly 70 per cent of patients were
> still alive three years after treatment with the durvalumab-based perioperative
> regimen. This EU approval brings patients the first immunotherapy regimen to extend
> survival in this early setting and is poised to become the new standard of care.”

> **Dave Fredrickson, Executive Vice President, Oncology Haematology Business Unit,
> AstraZeneca, said:** “This approval marks our third perioperative approval in 
> Europe for an _Imfinzi_-based regimen, underscoring AstraZeneca’s commitment to
> transforming outcomes in early-stage disease, where cure is possible. For patients
> with early gastric and gastroesophageal cancers, this immunotherapy-based regimen
> delivers a durable survival benefit that increases over time.”

In a planned interim analysis, patients treated with the _Imfinzi_-based perioperative
regimen showed a 29% reduction in the risk of disease progression, recurrence or
death versus chemotherapy alone (based on an event-free survival [EFS] hazard ratio[
HR] of 0.71; 95% confidence interval [CI] 0.58-0.86; p<0.001). Estimated median 
EFS was not yet reached for the _Imfinzi_ arm versus 32.8 months for the comparator
arm. An estimated 78.2% of patients treated with the _Imfinzi_-based perioperative
regimen were event-free at one year, compared to 74.0% in the comparator arm; the
estimated 24-month EFS rate was 67.4% versus 58.5%, respectively.

In the final overall survival (OS) analysis, results showed the _Imfinzi_ and FLOT
perioperative regimen demonstrated a statistically significant and clinically meaningful
survival improvement, reducing the risk of death by 22% compared to chemotherapy
alone (based on a HR of 0.78; 95% CI 0.63-0.96; p=0.021). An estimated 69% of patients
treated with the _Imfinzi_-based regimen were alive at three years compared with
62% in the comparator arm. At each subsequent prespecified OS landmark, the survival
curves indicated increasing separation, signaling a greater magnitude of benefit
over time for the _Imfinzi_-based regimen. An OS benefit was observed regardless
of tumour PD-L1 status. OS results from MATTERHORN were presented in a Proffered
Paper session at the European Society for Medical Oncology (ESMO) Congress 2025.

The safety profile for _Imfinzi_ and FLOT chemotherapy was consistent with the known
profiles of each medicine, and the percentage of patients that completed surgery
was similar compared to chemotherapy alone. Grade 3 or higher adverse events due
to any cause were similar between the two arms (71.6% for _Imfinzi_ and FLOT arm;
71.2% for comparator arm).

_Imfinzi_ and FLOT chemotherapy is approved in the US and other countries based 
on the MATTERHORN results. Regulatory applications are currently under review in
Japan and several other countries for this indication.

Share on:
